Stockscreener 앱 받기
3.11
6.87%
0.20
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
"NextEpochMarket company news.lhl"Results on X | Live Posts & Updates - x.com
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
Promising Clinical Trial Results for Lixte Biotechnology (LIXT) - GuruFocus
Ovarian cancer trial expands after 40% disease control in 20 patients - Stock Titan
Geopolitics Watch: How volatile is Lixte Biotechnology Holdings Inc stock2026 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
LIXTE Biotechnology Expands Cancer Treatment Strategy with Acquisition and Clinical Advancements - citybuzz -
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships - NewMediaWire
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships - TipRanks
Aug Reactions: What is the cash position of Lixte Biotechnology Holdings Inc2026 Fundamental Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
Lixte Biotech Advances Precision Oncology Strategy with LB-100 Therapy and Expanded Partnerships - citybuzz -
Valuation Update: Is Airship AI Holdings Inc part of any ETFPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Off: Is Lixte Biotechnology Holdings Inc attractive for institutional investors2026 Price Targets & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ETF Watch: Is Lixte Biotechnology Holdings Inc affected by consumer sentiment2026 Technical Overview & Daily Volume Surge Trade Alerts - baoquankhu1.vn
LIXT Technical Analysis & Stock Price Forecast - Intellectia AI
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - TipRanks
LIXTE Biotechnology Reports Transformational Year with Clinical Progress and Strategic Expansion - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - TipRanks
Lixte Biotech Receives Going Concern Alert Amid Insider and Institutional Sell-Offs—Who Will Fund the Recovery? - Bitget
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - NewMediaWire
LIXTE Biotechnology's LB-100 Emerges as Sole Clinical-Stage PP2A Inhibitor in Cancer Treatment Development - citybuzz -
LIXTE Biotechnology Reports Progress on LB-100 in 2025 Annual Report with Expanded Clinical Trials and Collaborations - geneonline.com
Cancer drug study doubles to 42 patients after LIXTE's $11M raise - Stock Titan
LIXTE Biotechnology’s Expanded Trial Could Be Its Best Shot at Breaking the Stagnation - Bitget
Lixte Biotechnology | 10-K: FY2025 Annual Report - Moomoo
Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS - TradingView — Track All Markets
Lixte Biotechnology (NASDAQ: LIXT) posts larger loss and flags going-concern risk - Stock Titan
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LIXTE Biotechnology Expands Clinical Trials for LB-100 in Challenging Ovarian and Colon Cancers - citybuzz -
Quarterly Earnings: Is Lixte Biotechnology Holdings Inc attractive for institutional investorsWeekly Trade Report & Daily Profit Focused Screening - baoquankhu1.vn
Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Lixte Biotechnology Stock: Precision Oncology Pioneer with High-Risk Development Pipeline for North - AD HOC NEWS
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership - Benzinga
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - The Globe and Mail
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming - NewMediaWire
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - The Globe and Mail
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
2.69%
0.25%
자본화:
|
볼륨(24시간):